AstraZeneca and Takeda Pharmaceutical Co., Ltd., have announced that they have entered an agreement to jointly develop and commercialize MEDI1341, an alpha-synuclein antibody in development as a potential treatment for Parkinson’s disease (PD).
Alpha-synuclein is an aggregation-prone protein that contributes to the development of PD. This protein is the major constituent of Lewy bodies, which are pathological protein aggregates that accumulate in the nerve cells of patients with PD and appear to spread throughout the nervous system during the progression of the disease. These insights support the development of new PD medicines that seek to remove existing pathological alpha-synuclein aggregates, prevent their formation, or stop them from spreading. Such therapies could potentially prevent or delay the onset of PD, or halt or slow its progression.
MEDI1341 is an antibody that is differentiated by its high affinity, high selectivity, and reduced effector function (lower interaction with the immune system), which has the potential to achieve a better efficacy and safety profile than other alpha-synuclein antibodies. MEDI1341 is due to enter phase 1 clinical trials later this year.
Under the terms of the agreement, AstraZeneca will lead phase 1 development while Takeda will lead future clinical development activities. The companies will share equally future development and commercialization costs for MEDI1341, as well as any future revenues. Takeda will pay AstraZeneca up to $400 million, including initial revenue in 2017, and development and sales milestones thereafter. Additional terms of the agreement are not disclosed.
Source: AstraZeneca; August 29, 2017.